national stem-cell therapy logo

Akari Therapeutics to Host Webinar on HSCT-TMA and the Potential of Nomacopan

Help Spread The Word, Share Post:

Akari Therapeutics, Plc, a leading biotechnology company specializing in advanced therapies for autoimmune and inflammatory diseases, has announced its plans to host a virtual key opinion leader event on October 19, 2023, at 11:30 am ET.

The primary focus of this event will be to discuss the patient care landscape for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). There is a significant need for earlier diagnosis and approved treatment options for HSCT-TMA, and this webinar aims to address these challenges.

One of the highlights of the event will be discussions surrounding Akari’s investigational drug, nomacopan. Nomacopan is a novel bispecific inhibitor that targets both complement C5 and leukotriene B4 (LTB4). The potential of nomacopan as a treatment for HSCT-TMA will be explored in depth during the webinar.

Esteemed speakers for the event include Sonata Jodele, MD, a Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at the University of Cincinnati Department of Pediatrics, and Professor Rob Wynn from the Royal Manchester Children’s Hospital, which is a part of Manchester University NHS Foundation Trust.

Additionally, the Akari management team will provide an overview of nomacopan and share updates on two ongoing Phase 3 clinical trials that are investigating the potential of nomacopan as a treatment for both pediatric and adult HSCT-TMA patients. The event will conclude with a live question and answer session.

About Akari Therapeutics:

Akari Therapeutics is a biotechnology company that is at the forefront of developing advanced therapies for autoimmune and inflammatory diseases. Their lead asset, nomacopan, is a bispecific recombinant inhibitor that has the potential to treat severe pediatric HSCT-TMA.

The company has received several designations from the FDA, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for nomacopan. The European Commission has also granted orphan drug designation to Akari for its work in hematopoietic stem cell transplantation.

For those interested in attending the webinar, registration is available, and a replay will be accessible post-event. More info here.

*** All content on is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

Stay Connected

More Updates